agilon health (NYSE:AGL) Upgraded by Citigroup to “Neutral” Rating

Citigroup upgraded shares of agilon health (NYSE:AGL) from a sell rating to a neutral rating in a research note published on Friday morning, MarketBeat.com reports. They currently have $2.25 target price on the stock, up from their previous target price of $1.75.

AGL has been the subject of several other reports. William Blair cut shares of agilon health from an “outperform” rating to a “market perform” rating in a research report on Friday, November 8th. Barclays decreased their price target on shares of agilon health from $5.00 to $2.00 and set an “underweight” rating for the company in a research note on Monday, November 11th. TD Cowen cut their price objective on agilon health from $6.00 to $2.00 and set a “hold” rating on the stock in a research report on Monday, November 11th. Needham & Company LLC assumed coverage on agilon health in a research report on Friday. They issued a “hold” rating for the company. Finally, Stifel Nicolaus dropped their price target on agilon health from $7.00 to $2.00 and set a “hold” rating on the stock in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $3.98.

agilon health Stock Up 10.5 %

NYSE AGL opened at $2.42 on Friday. agilon health has a 1 year low of $1.50 and a 1 year high of $8.20. The stock has a market capitalization of $997.08 million, a PE ratio of -2.57 and a beta of 0.53. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.29 and a quick ratio of 1.29. The business’s 50-day moving average is $2.07 and its 200 day moving average is $3.77.

agilon health (NYSE:AGL) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19). The business had revenue of $1.45 billion during the quarter, compared to the consensus estimate of $1.47 billion. agilon health had a negative return on equity of 47.84% and a negative net margin of 6.88%. During the same quarter in the prior year, the business posted ($0.06) earnings per share. Sell-side analysts forecast that agilon health will post -0.52 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Karen Mcloughlin bought 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average cost of $2.20 per share, with a total value of $55,000.00. Following the acquisition, the director now owns 73,166 shares in the company, valued at $160,965.20. This trade represents a 51.90 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John William Wulf purchased 45,000 shares of the business’s stock in a transaction on Thursday, December 5th. The shares were bought at an average cost of $2.18 per share, with a total value of $98,100.00. Following the acquisition, the director now directly owns 206,133 shares of the company’s stock, valued at $449,369.94. This trade represents a 27.93 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 90,000 shares of company stock valued at $198,100. 3.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. State Street Corp increased its holdings in agilon health by 3.0% in the 3rd quarter. State Street Corp now owns 7,449,706 shares of the company’s stock worth $29,277,000 after acquiring an additional 215,733 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of agilon health by 1.2% in the third quarter. Geode Capital Management LLC now owns 6,893,517 shares of the company’s stock worth $27,097,000 after purchasing an additional 84,889 shares during the period. Citigroup Inc. increased its stake in shares of agilon health by 2,251.5% in the third quarter. Citigroup Inc. now owns 2,028,246 shares of the company’s stock worth $7,971,000 after purchasing an additional 1,941,993 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of agilon health by 326.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,415,419 shares of the company’s stock valued at $5,563,000 after purchasing an additional 1,083,492 shares during the period. Finally, AQR Capital Management LLC lifted its stake in shares of agilon health by 3,338.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company’s stock valued at $8,871,000 after buying an additional 1,316,990 shares in the last quarter.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.